The Neuroprotective Effects of Lithium Chloride in a Model of Photochemically Induced Stroke

The aim of the study was to investigate the neuroprotective properties of lithium chloride in a model of photochemically induced stroke in rats.

Materials and Methods. The experimental work was conducted in the organoprotection laboratory for critical conditions at the V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology. The study included 32 outbred Wistar rats, randomized into 2 equal groups: the NaCl (control) group, treated with physiological saline solution, and the LiCl group, which received a 4.2% lithium chloride solution (63 mg/kg). The solutions were administered intravenously 120 minutes after inducing a stroke. The ischemic stroke model was generated using photochemically induced thrombosis in cerebral sensorimotor cortex vessels. Neurological deficit was assessed using the «limb placement test». Ischemic lesion volume was measured using MRI (7 Tesla). Immunohistochemical analysis included markers for NeuN (survived mature neurons), Cas-3 (neuronal apoptosis), and Iba-1 (microglial activation). Statistical analysis was performed using the Shapiro–Wilk test, Student's t-test, and the Mann–Whitney U test with significance at p < 0.05.

Results. Lithium chloride infusion resulted in a 30% reduction in the ischemic lesion volume compared to the control group (p = 0.0236). The LiCl group showed an increase in signal intensity (relative units, RU) in the NeuN-positive neurons in the penumbra (80 RU vs 41 RU in the control group, p = 0.0001), a 25% decrease in signal intensity in Cas-3-positive cells (p = 0.0008), and a 58% decrease in signal intensity in Iba-1-positive cells (p < 0.0001). Neurological deficit in the LiCl group was less detectable (NaCL vs LiCl: 9,8 ± 1,2 vs 12,5 ± 1,5 scores, respectively, p < 0.0001).

Conclusion. Lithium chloride demonstrated significant neuroprotective properties in a model of ischemic stroke, reducing the volume of damage and favoring the suppression of apoptosis and inflammation. The findings validate the potential of lithium chloride as a therapeutic agent for treatment of ischemic stroke, owing in particular to ability to modulate key pathogenic mechanisms of the disease. The results underscore the need for further clinical research to assess the efficacy and safety of lithium in medical practice.

1. Tolpygina S.N., Zagrebelny A.V., Chernysheva M.I., Voronina V.P., Kutishenko N.P., Dmitrieva N.A., Lerman O.V., et al. Long-term survival of patients with acute cerebrovascular accidents in different age groups in the REGION-M registry. Russian Journal of Cardiology=Rossiyskiy Kardiologichesky Zhurnal. 2023; 28 (2): 5250. (In Russ.). DOI: 10.15829/1560-4071-2023-5250.

2. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5): 439-458. DOI: 10.1016/S1474-4422(19)30034-1. PMID: 30871944.

3. Cheng J., Zheng Y., Cheng F., Wang C., Han J., Zhang H., Lan X., et al. Different roles of astrocytes in the blood-brain barrier during the acute and recovery phases of stroke. Neural Regen Res. 2026; 21(4): 1359–1372. DOI: 10.4103/NRR.NRR-D-24-01417. PMID: 40537147.

4. Yang J., Wu S., He M. Extracellular vesicle-mediated delivery of mitochondrial circRNA MTCO2 protects against cerebral ischemia by modulating mPTP-dependent ferroptosis. Redox Biol. 2025; 86: 103806. DOI: 10.1016/j.redox.2025.103806. PMID: 40768899.

5. Likhvantsev V.V., Moroz V.V., Grebencchikov O.A. The mechanisms of pharmacological preconditioning of the brain and the comparative efficacy of the drugs – direct-and indirect-acting glycogen synthase kinase-3 inhibitors: experimental study. General Reanimatology = Obshchaya Reanimatologiya. 2012; 8 (6): 37–42. (in Russ.&Eng.). DOI: 10.15360/1813-9779-2012-6-37.

6. Karati D., Meur S., Roy S., Mukherjee S., Debnath B., Jha S.K., Sarkar B.K., Naskar S., et al. Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2025; 398 (3): 2319–2342. DOI: 10.1007/s00210-024-03500-1. PMID: 39432068.

7. Allam E., Abdel Ghafar S.K., Hussein M., Al-Emam A., Radad K. Lithium chloride rescues dopaminergic neurons in a Parkinson’s disease rat model challenged with rotenone. CNS Neurol Disord Drug Targets. 2025; 24 (8): 636–647. DOI: 10.2174/0118715273365449250224090655. PMID: 40114566.

8. Godoy J.A., Mira R.G., Inestrosa N.C. Intracellular effects of lithium in aging neurons. Ageing Res Rev. 2024; 99: 102396. DOI: 10.1016/j.arr.2024.102396. PMID: 38942199.

9. Sharikadze D.T., Gabitov M.V., Redkin I.V., Kuzovlev A.N., Moroz V.V. Neuroprotective potential of lithium chloride in a model of traumatic brain injury. General Reanimatology = Obshchaya Reanimatologiya. 2025; 21 (5): 44–50. DOI: 10.15360/1813-9779-2025-5-2528.

10. Cherpakov R.A., Grebencchikov O.A. Effect of lithium chloride concentration on its neuroprotective properties in ischemic stroke in rats. General Reanimatology = Obshchaya Reanimatologiya. 2021; 17 (5): 101–110. (in Russ.&Eng.). DOI: 10.15360/1813-9779-2021-5-101-110.

11. Sharikadze D.T., Gabitov M.V., Lobanov A.V., Grebenshchikov O.A., Kuzovlev A.N. The effect of lithium chloride on the level of pro-inflammatory cytokines after traumatic brain injury. Pathological Physiology and Experimental Therapy= Patologicheskaya Fiziologiya i Exsperimentalnaya Terapiya. 2025; 69 (1): 58–64. (in Russ.). DOI: 10.25557/0031-2991.2025.01.

12. De-Paula V.J.R., Radanovic M., Forlenza O.V. Lithium and neuroprotection: a review of molecular targets and biological effects at subtherapeutic concentrations in preclinical models of Alzheimer’s disease. Int J Bipolar Disord. 2025; 13 (1): 16. DOI: 10.1186/s40345-025-00386-7. PMID: 40348943.

13. Gildengers A.G., Ibrahim T.S., Zeng X., Aizenstein H.J., Alkhateeb S.K., Anderson S.J., Chu C., et al. The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment. Alzheimers Dement (NY). 2025; 11 (2): e70112. DOI: 10.1002/trc2.70112. PMID: 40501510.

14. Boll M.C., Alcaraz-Zubeldia M., Rios C., González-Esquivel D., Montes S. A phase 2, double-blind, placebo-controlled trial of a valproate/lithium combination in ALS patients. Neurologia.2025; 40 (1): 32–40. DOI: 10.1016/j.nrleng.2022.07.003. PMID: 36049647.

15. Puglisi-Allegra S., Ruggieri S., Fornai F. Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders. Transl Psychiatry. 2021; 11: 1–10. DOI: 10.1038/s41398-021-01492-7. PMID: 34226487.

16. Gogoleva I.V., Gromova O.A., Torshin I.Y., Grishina T.R., Pronin A.V. The neurobiological role of lithium salts. Neurosci Behav Physi. 2023; 53: 939 945. DOI: 10.1007/s11055-023-01485-7.

17. Singulani M.P., Ferreira A.F.F., Figueroa P.S., Cuyul-Vásquez I., Talib L.L., Britto L.R., Forlenza O.V. Lithium and disease modification: a systematic review and meta-analysis in Alzheimer’s and Parkinson’s disease. Ageing Res Rev. 2024; 95: 102231. DOI: 10.1016/j.arr.2024.102231. PMID: 38364914.

18. Almeida O.P., Singulani M.P., Ford A.H., Hackett M.L., Etherton-Beer C., Flicker L., Hankey G.J., et al. Lithium and stroke recovery: a systematic review and meta-analysis of stroke models in rodents and human data. Stroke. 2022; 53: 2935–2944. DOI: 10.1161/STROKEAHA.122.039203. PMID: 35968702.

19. Fan M., Song C., Wang T., Li L., Dong Y., Jin W., Lu P. Protective effects of lithium chloride treatment on repeated cerebral ischemia-reperfusion injury in mice. Neurological Sciences. 2015; 36 (2): 315–321. DOI: 10.1007/s10072-014-1943-x. PMID: 25192664.

20. Pronin A.V., Gromova O.A., Sardaryan I.S., Torshin I., Stelmashuk E.V., Ostrenko K.S, Aleksandrova O.P., et al. The adaptogenic and neuroprotective properties of lithium ascorbate. Neuroscience and Behavioral Physiology. 2018; 48 (4): 409–415. DOI: 10.1007/s11055-018-0579-3.

21. Yuan X., Li W., Yan Q., Ou Y., Long Q., Zhang P. Biomarkers of mature neuronal differentiation and related diseases. Future Sci OA. 2024; 10 (1): 2410146. DOI: 10.1080/20565623.2024.2410146. PMID: 39429212.

22. Green T.R.F., Rowe R.K. Quantifying microglial morphology: an insight into function. Clin Exp Immunol. 2024; 216 (3): 221–229. DOI: 10.1093/cei/uxae02. PMID: 38456795.

23. De Ryck M., Van Reempts J., Borgers M., Wauquier A., Janssen P.A. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke.1989; 20 (10): 1383–90. DOI: 10.1161/01.str.20.10.1383. PMID: 2799870.

24. Jolkkonen J., Puurunen K., Rantakömi S., Härkönen A., Haapalinna A., Sivenius J. Behavioral effects of the alpha(2)-adrenoceptor antagonist, atipamezole, after focal cerebral ischemia in rats. Eur J Pharmacol. 2000; 400 (2–3): 211–219. DOI: 10.1016/s0014-2999(00)00409-x. PMID: 10988336.

25. Ghanaatfar F., Ghanaatfar A., Isapour P., Farokhi N., Bozorgniahosseini S., Javadi M., Gholami M., et al. Is lithium neuroprotective? An updated mechanistic illustrated review. Fundam Clin Pharmacol. 2023; 37 (1): 4–30. DOI: 10.1111/fcp.12826. PMID: 35996185.

26. Ates N., Caglayan A., Balcikanli Z., Sertel E., Beker M.C., Dilsiz P., Caglayan A.B., et al. Phosphorylation of PI3K/Akt at Thr308, but not phosphorylation of MAPK kinase, mediates lithium-induced neuroprotection against cerebral ischemia in mice. Exp Neurol. 2022; 351: 113996. DOI: 10.1016/j.expneurol.2022.113996. PMID: 35122865.

27. Wang W., Lu D., Shi Y., Wang Y. Exploring the neuroprotective effects of lithium in ischemic stroke: a literature review. Med Sci. 2024; 21 (2): 284–298. DOI: 10.7150/ijms.88195. PMID: 38169754.

28. Ghribi O., Herman M., Spaulding N.K., Savory J. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. Journal of Neurochemistry. 2002; 82 (1): 137–145. DOI: 10.1046/j.1471-4159.2002.00957.x. PMID: 12091474.

29. King T.D., Bijur G.N., Jope R.S. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithium. Brain Research. 2001; 919 (1): 106–114. DOI: 10.1016/S0006-8993(01)03041-2.

30. Habib M.Z., Ebeid M.A., Faramawy Y., Saad S.S., Magdoub H.M., Attia A.A., Aboul-Fotouh S., et al. Effects of lithium on cytokine neuro-inflammatory mediators, Wnt/β-catenin signaling and microglial activation in the hippocampus of chronic mild stress-exposed rats. Toxicol Appl Pharmacol. 2020; 399: 115073. DOI: 10.1016/j.taap.2020.115073. PMID: 32454056.

31. Sakrajda K., Rybakowski J.K. The mechanisms of lithium action: the old and new findings. Pharmaceuticals (Basel). 2025; 18 (4): 467. DOI: 10.3390/ph18040467.

32. Bortolozzi A., Fico G., Berk M., Solmi M., Formaro M., Quevedo J., Zarate C.A., et al. New advances in the pharmacology and toxicology of lithium: a neurobiologically oriented overview. Pharmacol Rev. 2024; 76 (3): 323–357. DOI: 10.1124/pharmrev.120.000007.